ALMS
HealthcareAlumis Inc. Common Stock · Biotechnology · $3B
What is Alumis Inc. Common Stock?
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and neuroinflammatory diseases. Headquartered in South San Francisco, California, the company is building a pipeline centered on a novel class of TYK2 inhibitors.
Alumis generates no commercial revenue yet, as it remains in the clinical development phase. The company is advancing two drug candidates: ESK-001, targeting plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, designed to penetrate the central nervous system for neuroinflammatory and neurodegenerative conditions. Both candidates work through allosteric inhibition of the TYK2 enzyme, a mechanism that has attracted significant attention in autoimmune drug development.
Alumis was incorporated in 2021 — formerly operating as Esker Therapeutics — and is based in South San Francisco, California.
- ESK-001 — allosteric TYK2 inhibitor for plaque psoriasis
- ESK-001 — development program for systemic lupus erythematosus
- ESK-001 — program for non-infectious uveitis
- A-005 — CNS-penetrant TYK2 inhibitor for neuroinflammation and neurodegeneration
Is ALMS a Good Stock to Buy?
UQS Score rates ALMS as Poor overall, reflecting the early-stage nature of the business and the significant uncertainties that come with a pre-revenue clinical company.
The Growth and Risk pillars are the relative bright spots in the ALMS profile. The pipeline addresses large, underserved patient populations, and the TYK2 inhibitor mechanism has demonstrated clinical validation elsewhere in the autoimmune space. The Risk pillar rating suggests the company's near-term financial structure is not among the most precarious in the sector.
Quality and Moat both register as Weak, which is typical for clinical-stage biotechs with no approved products and no established commercial franchise. Valuation is rated Elevated, meaning the market may already be pricing in optimistic pipeline outcomes.
Pro members can see the exact pillar breakdown and the full financial metrics behind each rating — sign up to access the complete ALMS analysis. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ALMS pay dividends?
No — Alumis Inc. Common Stock does not currently pay a dividend.
Alumis does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials and advancing the pipeline toward potential regulatory approval. Income-focused investors should not expect distributions from ALMS in the near term.
When does ALMS report earnings?
Alumis reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, Alumis's quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue and profit metrics. Pipeline milestones and trial readouts tend to be the most market-moving disclosures.
For the most recent quarter's results and management commentary, visit Alumis's investor relations page directly.
ALMS Price History
+87.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Alumis Inc. Common Stock?
Based on Alumis Inc. Common Stock's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ALMS Long-term Outlook
The fundamental outlook for Alumis is shaped almost entirely by clinical execution. The Good Growth pillar rating reflects the potential scale of the autoimmune and neuroinflammatory markets the company is targeting. However, the Weak Quality and Moat ratings underscore that no durable competitive position has yet been established — that can only come with approved products. The Elevated Valuation rating suggests investors are already embedding meaningful pipeline success into the current price, which amplifies downside risk if trials disappoint.
Growth drivers
- Large addressable markets in plaque psoriasis and lupus with unmet patient need
- Growing clinical and commercial validation of the TYK2 inhibitor drug class
- Potential pipeline expansion into neuroinflammatory indications via A-005
Key risks
- Clinical trial failure or unexpected safety signals in either program
- Elevated valuation leaves limited margin of safety if milestones slip
- Ongoing cash consumption with no commercial revenue to offset expenses
ALMS vs Peers
Alumis competes within a broader landscape of clinical-stage and commercial-stage companies targeting autoimmune and inflammatory diseases.
Tango focuses on precision oncology through synthetic lethality, giving it a different therapeutic focus than Alumis's autoimmune-centered pipeline.
Arcutis has advanced further toward commercialization in dermatology, including plaque psoriasis, making it a more direct competitive reference point for ESK-001.
Vera targets kidney disease driven by autoimmune mechanisms, overlapping with Alumis in the broader immunology space while pursuing distinct patient populations.
Frequently Asked Questions
What does Alumis Inc. do?
Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and neuroinflammatory diseases. Its lead program, ESK-001, is a TYK2 inhibitor being studied in plaque psoriasis, lupus, and uveitis. A second candidate, A-005, targets neuroinflammatory and neurodegenerative conditions through the same mechanism.
Does ALMS pay dividends?
No. Alumis does not pay a dividend. The company is pre-revenue and directs its capital toward clinical development. Dividend payments are not typical for clinical-stage biotechs and are unlikely until the company reaches commercial profitability.
When does ALMS report earnings?
Alumis reports on a quarterly basis, as required for US-listed public companies. Because it has no commercial revenue, reports center on operating expenses and pipeline updates. Check Alumis's investor relations page for the current reporting schedule.
Is ALMS a good stock to buy?
UQS Score rates ALMS as Poor overall. The Growth and Risk pillars offer relative positives, but Quality and Moat are both Weak, and Valuation is Elevated. Whether the pipeline potential justifies the current price depends on an investor's risk tolerance and clinical outlook. See the full pillar breakdown on UQS Score for a structured view.
Is ALMS overvalued?
UQS Score's Valuation pillar for ALMS is rated Elevated, suggesting the market may already be pricing in favorable clinical outcomes. For a pre-revenue biotech, valuation is inherently speculative and tied closely to trial results rather than current earnings power.
How does ALMS compare to its competitors?
Among peers like Arcutis Biotherapeutics and Vera Therapeutics, Alumis is distinguished by its focus on allosteric TYK2 inhibition across multiple autoimmune indications. Arcutis has progressed further in dermatology commercialization, while Alumis remains earlier-stage but with a broader potential indication set.
What is ALMS's market cap bracket?
Alumis is classified as a mid-cap company. For a clinical-stage biotech with no approved products, this reflects market expectations around pipeline value rather than current revenue or earnings.
Who founded Alumis Inc.?
Alumis was incorporated in 2021, originally under the name Esker Therapeutics, Inc., before rebranding in January 2022. Founding details are publicly available through the company's SEC filings and investor relations materials.
Is ALMS a long-term quality investment?
From a long-term quality standpoint, UQS Score rates ALMS as Poor, with Weak scores on both Quality and Moat. Clinical-stage biotechs can improve these ratings significantly if they achieve regulatory approvals and build a commercial franchise, but that outcome is not yet reflected in the fundamentals.
What is the main competitive advantage of Alumis?
Alumis's potential differentiation lies in its allosteric TYK2 inhibitor approach, which targets the same pathway as approved competitors but through a distinct binding mechanism. If clinical data supports a favorable efficacy and safety profile, this could become a meaningful differentiator — though that remains to be proven.
What sector does ALMS belong to?
Alumis operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. The company's focus on autoimmune and neuroinflammatory diseases places it in one of the more active areas of drug development within that sector.
Unlock Full ALMS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓See the exact UQS Score and all five pillar ratings
- ✓View full financial metrics and trend data
- ✓Compare ALMS against sector peers on each pillar
- ✓Access the complete risk and valuation breakdown
- ✓Track score changes as new data is released
Pro Analysis
ALMS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 17, 2026 | 20.5 | 2.1 | 11.0 | 30.1 | 74.6 | 0.0 | -3.4 |
| May 16, 2026 | 23.9 | 2.1 | 11.0 | 47.3 | 74.6 | 0.0 | +0.1 |
| May 11, 2026 | 23.8 | 2.1 | 11.0 | 47.3 | 74.1 | 0.0 | +0.5 |
| May 10, 2026 | 23.3 | 0.0 | 11.0 | 47.3 | 74.1 | 0.0 | -0.5 |
| May 4, 2026 | 23.8 | 2.1 | 11.0 | 47.3 | 74.1 | 0.0 | -1.5 |
| Apr 22, 2026 | 25.3 | 2.1 | 11.0 | 54.5 | 74.1 | 0.0 | -2.7 |
| Apr 2, 2026 | 28.0 | 2.1 | 11.0 | 68.2 | 74.1 | 0.0 | — |
ALMS — Pillar Breakdown
Quality
— 2.1/100 (25%)Alumis Inc. Common Stock currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 30.1/100 (20%)Alumis Inc. Common Stock faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.6/100 (15%)Alumis Inc. Common Stock maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Alumis Inc. Common Stock appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Alumis Inc. Common Stock operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ALMS.
Score Composition
Financial Data
More Stock Analysis
How is the ALMS UQS Score Calculated?
The UQS (Unified Quality Score) for Alumis Inc. Common Stock is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Alumis Inc. Common Stock's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Alumis Inc. Common Stock is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.